JP2010514828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514828A5 JP2010514828A5 JP2009544447A JP2009544447A JP2010514828A5 JP 2010514828 A5 JP2010514828 A5 JP 2010514828A5 JP 2009544447 A JP2009544447 A JP 2009544447A JP 2009544447 A JP2009544447 A JP 2009544447A JP 2010514828 A5 JP2010514828 A5 JP 2010514828A5
- Authority
- JP
- Japan
- Prior art keywords
- propyl
- oxadiazol
- piperidine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 oxadiazol-5-yl Chemical group 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- DYWOLPXRUNVGOO-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 DYWOLPXRUNVGOO-UHFFFAOYSA-N 0.000 claims 1
- DPSQJTZWTDOKFO-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 DPSQJTZWTDOKFO-UHFFFAOYSA-N 0.000 claims 1
- IATPCIBOIGPQOH-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 IATPCIBOIGPQOH-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *C(CCOc1cc(*)c(*)cc1)C(CC1)CCN1C1NC(*)=**1 Chemical compound *C(CCOc1cc(*)c(*)cc1)C(CC1)CCN1C1NC(*)=**1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700123A GB0700123D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
| GB0719760A GB0719760D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
| PCT/GB2008/050010 WO2008081204A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514828A JP2010514828A (ja) | 2010-05-06 |
| JP2010514828A5 true JP2010514828A5 (OSRAM) | 2011-02-17 |
Family
ID=39203133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544447A Pending JP2010514828A (ja) | 2007-01-04 | 2008-01-04 | ピペリジンｇｐｃｒアゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100048632A1 (OSRAM) |
| EP (2) | EP2114933B1 (OSRAM) |
| JP (1) | JP2010514828A (OSRAM) |
| AT (1) | ATE523507T1 (OSRAM) |
| BR (1) | BRPI0806498A2 (OSRAM) |
| CA (1) | CA2674348A1 (OSRAM) |
| CY (1) | CY1112483T1 (OSRAM) |
| DK (1) | DK2114933T3 (OSRAM) |
| EA (1) | EA015129B1 (OSRAM) |
| ES (1) | ES2373181T3 (OSRAM) |
| HR (1) | HRP20110852T1 (OSRAM) |
| PL (1) | PL2114933T3 (OSRAM) |
| PT (1) | PT2114933E (OSRAM) |
| RS (1) | RS52065B (OSRAM) |
| SI (1) | SI2114933T1 (OSRAM) |
| WO (1) | WO2008081204A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| BR112012000831A2 (pt) | 2009-06-24 | 2019-09-24 | Boehringer Ingelheim Int | compostos, composições farmacêuticas e métodos relacionados |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2611433A2 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| IN2013DN02552A (OSRAM) | 2010-09-01 | 2015-08-07 | Arena Pharm Inc | |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9944600B2 (en) | 2012-06-12 | 2018-04-17 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for GPR119 agonist |
| AU2014354488B2 (en) | 2013-11-26 | 2017-08-24 | Chong Kun Dang Pharmaceutical Corp. | Amide derivatives for GPR119 agonist |
| KR101726819B1 (ko) | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
| DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
| AU7193394A (en) | 1993-08-13 | 1995-03-14 | Zeneca Limited | Thia- and oxadiazole derivatives and their use as fungicides or insecticides |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| WO1998006720A1 (fr) | 1996-08-09 | 1998-02-19 | Eisai Co., Ltd. | Derives de benzopiperidine |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| WO2000012704A2 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| GB0109103D0 (en) | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| EP1421077A4 (en) | 2001-08-31 | 2004-11-17 | Univ Connecticut | NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| US6974810B2 (en) | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| CA2456606C (en) | 2001-09-21 | 2010-01-26 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| EP1482794A1 (en) | 2002-03-06 | 2004-12-08 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| CA2479618A1 (en) | 2002-03-26 | 2003-10-09 | William K. Hagmann | Spirocyclic amides as cannabinoid receptor modulators |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| CA2480856A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| WO2003086288A2 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| BR0313041A (pt) | 2002-07-29 | 2005-06-21 | Hoffmann La Roche | Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos |
| CA2494091C (en) | 2002-08-02 | 2011-02-01 | Richard B. Toupence | Substituted furo [2,3-b| pyridine derivatives |
| US20050101542A1 (en) | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| WO2004029204A2 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| AU2003267728A1 (en) | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| KR100704097B1 (ko) | 2003-01-02 | 2007-04-06 | 에프. 호프만-라 로슈 아게 | 신규 ｃｂ 1 수용체 역작용제 |
| WO2004060888A1 (en) | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Novel cb 1 receptor inverse agonists |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| KR20050111588A (ko) | 2003-02-13 | 2005-11-25 | 사노피-아벤티스 도이칠란트 게엠베하 | 치환된 헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온유도체, 이의 제조방법 및 약제로서의 이의 용도 |
| EP1597259B1 (de) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
| KR20070083939A (ko) | 2004-11-02 | 2007-08-24 | 반유 세이야꾸 가부시끼가이샤 | 아릴옥시 치환된 벤즈이미다졸 유도체 |
| MX2007007553A (es) | 2004-12-24 | 2007-08-15 | Prosidion Ltd | Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes. |
| US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP2008545009A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| US20090203676A1 (en) | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
| JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| NZ571869A (en) * | 2006-04-06 | 2011-11-25 | Prosidion Ltd | Heterocyclic GPCR agonists |
-
2008
- 2008-01-04 AT AT08702095T patent/ATE523507T1/de active
- 2008-01-04 US US12/522,015 patent/US20100048632A1/en not_active Abandoned
- 2008-01-04 WO PCT/GB2008/050010 patent/WO2008081204A1/en not_active Ceased
- 2008-01-04 DK DK08702095.4T patent/DK2114933T3/da active
- 2008-01-04 EP EP08702095A patent/EP2114933B1/en active Active
- 2008-01-04 ES ES08702095T patent/ES2373181T3/es active Active
- 2008-01-04 SI SI200830454T patent/SI2114933T1/sl unknown
- 2008-01-04 EP EP11174256A patent/EP2377863A1/en not_active Withdrawn
- 2008-01-04 CA CA002674348A patent/CA2674348A1/en not_active Abandoned
- 2008-01-04 HR HR20110852T patent/HRP20110852T1/hr unknown
- 2008-01-04 BR BRPI0806498-9A2A patent/BRPI0806498A2/pt not_active IP Right Cessation
- 2008-01-04 EA EA200900877A patent/EA015129B1/ru not_active IP Right Cessation
- 2008-01-04 PL PL08702095T patent/PL2114933T3/pl unknown
- 2008-01-04 PT PT08702095T patent/PT2114933E/pt unknown
- 2008-01-04 JP JP2009544447A patent/JP2010514828A/ja active Pending
- 2008-01-04 RS RS20110523A patent/RS52065B/sr unknown
-
2011
- 2011-11-25 CY CY20111101161T patent/CY1112483T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514828A5 (OSRAM) | ||
| HRP20110852T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| JP2010514832A5 (OSRAM) | ||
| JP2022096662A5 (OSRAM) | ||
| JP2007523181A5 (OSRAM) | ||
| ES2376015T3 (es) | Agonistas de gpcr de tipo piperidina. | |
| JP2011500658A5 (OSRAM) | ||
| JP2013519680A5 (OSRAM) | ||
| JP2011500659A5 (OSRAM) | ||
| EP3022202A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| US8822510B2 (en) | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | |
| JP2010519243A5 (OSRAM) | ||
| JP2009519965A5 (OSRAM) | ||
| JP2013523819A (ja) | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 | |
| RU2006127572A (ru) | Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| EA018703B1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| JP2013507366A5 (OSRAM) | ||
| JP2010513319A5 (OSRAM) | ||
| JP2008500337A5 (OSRAM) | ||
| TW201113277A (en) | New thiadiazole derivatives | |
| JP2008526724A5 (OSRAM) | ||
| RU2009138219A (ru) | Новые бензамидные производные и способ их получения | |
| JP2007508360A5 (OSRAM) | ||
| JP2004502670A5 (OSRAM) | ||
| JP2007511485A5 (OSRAM) |